AzTrials
AzTrials

Smoking CessationNCT03836560

Comparing the Effectiveness of Combined NRT With Single NRT in Primary Care Clinics in Hong Kong

A study testing Nicotine patch and Nicotine gum in people with Smoking Cessation, run by Hospital Authority, Hong Kong.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The prevalence of cigarette smoking has dropped to 10% in Hong Kong (HK) in 2017, however, smoking still kills 5700 persons per year. Studies suggest that abstinence rates are higher with combined NRT than single NRT, although local data on safety and benefits of combined NRT are lacking. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Smoking Cessation
What is being tested?
Nicotine patch and Nicotine gum
Could I receive a placebo?
No, everyone receives an active treatment
How many people
560 participants
Where
No sites listed yet
Study dates
18 Dec 2012to 28 Feb 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • current smokers who smoke 10 or more cigarettes a day for at least one year

Who cannot join

  • unstable angina
  • severe cardiac arrhythmia
  • recent acute myocardial infarction or cerebrovascular accident in preceding 3 months
  • below 18 years old
  • being pregnant or on breast-feeding
  • unable to use gum
  • with a previous history of failure to NRT
  • with a history of hypersensitivity to nicotine

About this study

Official title: Comparing the Effectiveness of Nicotine Patch With Gum Versus Nicotine Patch Alone in Smoking Cessation in Hong Kong Primary Care Clinics

The prevalence of cigarette smoking has dropped to 10% in Hong Kong (HK) in 2017, however, smoking still kills 5700 persons per year. Studies suggest that abstinence rates are higher with combined NRT than single NRT, although local data on safety and benefits of combined NRT are lacking.

This is a one-year, two-arm, parallel randomized trial in 20 HK public clinics. The aim is to compare the effectiveness of combined NRT with single NRT among HK Chinese. 560 chronic smokers, who smoked ≥10 cigarettes/day for ≥ 1 year, were randomized to either intervention or usual care.

Intervention group received counseling and nicotine patch \& gum. Usual care group received counselling and nicotine patch only. Primary outcome was smoking abstinence rate at 52 weeks. Secondary outcomes included smoking abstinence rate at 4, 12, \& 26 weeks. Crude odds ratio (combined NRT vs. single NRT) and p-value were reported from logistic regression without adjustment; for trend analysis, adjusted odds ratio (AOR) and p-value were reported from Generalized Estimating Equation (GEE) (controlling for time). All AORs were adjusted for age, sex, baseline CO and clusters.

Read the detailed description

Background Globally, smoking causes six million deaths a year1. By 2030, if current trends continue, the number of deaths will rise to eight million. According to Hong Kong Thematic Household Survey Reports, although the prevalence of current smokers among aged 15 and over has dropped from 15.3% in 2006 to 10.8% in 2017 in Hong Kong, smoking still kills 5700 persons per year and contributes to 14% of all deaths from non-communicable diseases. Thus, enhancement in smoking cessation would be crucial in improving health all smokers.

Among all pharmacological treatment for smoking cessation, evidences showed that oral treatment such as Varenicline is the most clinically effective smoking cessation medication9. However, there have been concerns about its adverse effect on neuropsychiatric and cardiovascular aspects. Besides, many smokers are reluctant to use it due to fear of its high rate of side effects and being medicalized for smoking cessation. The use of nicotine replacement therapy (NRT) has been largely studied, and, over the last decade, many studies had been carried out to compare the effect of monotherapy with combined nicotine replacement therapy. While the effect of monotherapy had been found to be small in heavy smokers due to significant withdrawal symptoms, combined NRT is believed to provide a stable baseline nicotine level by means of nicotine patch plus intermittent usage of short acting NRT e.g. gums, lozenges or inhalers for withdrawal symptoms. Several studies have shown that combined NRT is associated with lower withdrawal scores and higher 6-month quit rates (26.9 to 36.9%) when compared with monotherapies (19-23%)18-21. Combined NRT has also been shown to be safe as trials of combining various NRTs did not report that combination treatment produced increased adverse events.

In Hong Kong, Hospital Authority is one of the major service providers for smoking cessation. The target recipients of our smoking cessation service are primarily patients attending public general out-patient clinics (GOPCs) for management of chronic illnesses such as hypertension and diabetes mellitus, as well as patients with episodic complaints. Through effective interventions provided in the smoking cessation service, it is aimed that their medical conditions could be further improved. However, as majority of these smokers have moderate or above nicotine dependence, how effective is combined NRT compared to single NRT in this Chinese population is unknown.

Hypothesis:

Combined NRT gives a higher abstinence rate than single NRT.

Objective:

This study aims to compare the effectiveness of combined NRT with single NRT in Hong Kong primary care clinics.

Assessment Patients were seen at baseline for assessment, and then at 4 weeks, 12 weeks, 26 weeks and 52 weeks. Study medication was given at baseline and at week 4. In baseline assessment, smoking history including daily cigarette consumption and past quitting method, past medical health, drug history and allergy would be obtained. In follow up visits patients were assessed on nicotine withdrawal symptoms, carbon monoxide level, side effects from treatment and medication compliance. Counselling would be given in all follow up visits.

Pharmacological interventions Patients were randomized to either intervention or usual care for smoking cessation. Nicotine replacement therapy (NRT) was given for 8 weeks in both arms. Intervention consisted of counseling and combined NRT of nicotine patch and gum. Usual care involved counseling and single NRT of nicotine patch. NRT patch regimen used in usual care was the same as that in intervention group.

Data analysis Baseline characteristics were reported and compared by treatment groups, two-sample t test was conducted for continuous variables and Chi-square test for categorical variables. At each visit, crude odds ratio (OR) (combined NRT vs. single NRT) was reported, simple logistic regression was utilized without adjustment first, and then adjusted for potential confounders, age, sex, baseline CO level and cluster site of the subject recruitment. The overall treatment effect (combined NRT vs. single NRT) over the study period was estimated by Generalized Estimating Equation (GEE). In the GEE model, time (repeated measures at 4, 12, 26, and 52 weeks) was included as a continuous covariate, adjusted odds ratio (AOR) was reported and treatment-time interaction was tested. Potential confounders were also adjusted for in the GEE model. As GEE only uses non-missing records, missing at complete random was assumed to avoid bias. To support the random missing assumption, supplementary analysis was conducted for missingness pattern Furthermore, imputation was conducted under a conservative scenario of 'all missing records as "failure", i.e., not quit'. Statistical significance level was set at two-sided p<0.05 for all tests. Analysis was conducted by R version 3.2.235. Side effects from NRT were also recorded from both groups. Chi-squared test was used to compare the difference.

Being tested
Nicotine patch, Nicotine gum
Keywords
nicotine replacement therapy, smoking cessation, quit rates
Medical subject headings
Smoking Cessation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Nicotine patchDrug

    nicotine patch given for 8 weeks

  • Nicotine gumDrug

    nicotine gum given as requested

Study groups in NCT03836560
Study groupRoleWhat they receive
Usual groupActive comparatorUsual group with nicotine patch only: Usual care involved counseling and 8 weeks of single NRT of nicotine patch. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches.
Receives: Drug: Nicotine patch
Intervention groupActive comparatorNicotine patch and nicotine gum: Intervention consisted of counseling and 8 weeks of combined NRT of nicotine patch and gum. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches. 2mg nicotine gum was used once every 1 to 2 hours when required.
Receives: Drug: Nicotine patch; Drug: Nicotine gum

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 7-day point-prevalence abstinence rate at 52 weeks after quit date

    During initial assessment, patient will set a quit date with the counsellor. At 52 weeks after the quit rate, counsellor will call the patient and confirm his quit status. The status was confirmed by self reporting abstinence rate and exhaled carbon monoxide level

    Measured: at 52 weeks after the agreed quit date

Secondary outcomes (2)
  1. side effects profiles

    side effects from nicotine replacement therapy

    Measured: up to 1 year

  2. 7-day point-prevalence of abstinence rate at 26 weeks after quit date

    During initial assessment, patient will set a quit date with the counsellor. At 26 weeks after the quit rate, counsellor will call the patient and confirm his quit status. The status was confirmed by self reporting abstinence rate and exhaled carbon monoxide level

    Measured: at 26 weeks after the agreed quit date

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Feb 2019
  2. Study start18 Dec 2012
  3. Primary completion28 Feb 2018
  4. Study completion28 Feb 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
One year, 2 arm, parallel, randomised controlled trial
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
560 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03836560
Sponsor's protocol ID
HA_SCCP_NRT
Status last verified
Feb 2019
First submitted
30 Jan 2019
Last updated
11 Feb 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: We plan to provide a dropbox link

Publications

  • Theodoulou A, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J, Livingstone-Banks J, Hajizadeh A, Lindson N. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2023 Jun 19;6(6):CD013308. doi: 10.1002/14651858.CD013308.pub2.

    PubMed 37335995
  • Leung MKW, Bai D, Yip BHK, Fong MY, Lai PMH, Lai P, Lai ISY, Lam ZHW, Leung ATF, To DKY, Wong MT, Wong TK, Chao DVK. Combined nicotine patch with gum versus nicotine patch alone in smoking cessation in Hong Kong primary care clinics: a randomised controlled trial. BMC Public Health. 2019 Oct 16;19(1):1302. doi: 10.1186/s12889-019-7634-z.

    PubMed 31619205

Questions about this trial

What is this clinical trial studying?

A study testing Nicotine patch and Nicotine gum in people with Smoking Cessation, run by Hospital Authority, Hong Kong.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

7-day point-prevalence abstinence rate at 52 weeks after quit date (time frame: at 52 weeks after the agreed quit date). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03836560, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in